1. The CYP/20-HETE/GPR75 axis in hypertension
Ghezal Froogh, Victor Garcia and Michal L. Schwartzman
2. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury
John D Imig
3. Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation
Annika A. Jüttner, A.H. Jan Danser and Anton J.M. Roks
4. Sphingosine-1-phosphate and sphingosine-1-phosphate receptors in the cardiovascular system: Pharmacology and clinical implications
Simona Federica Spampinato, Maria Angela Sortino and Salvatore Salomone
5. Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease
Dominique Brown, Heather Alcala, Peter Oelschlaeger and Bradley T. Andresen
6. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension
Prasad Chunduri, Shrey A. Patel and Scott P. Levick
7. Cardiovascular effects of GLP-1 receptor agonism
Raymond J. Winquist and Valentin K. Gribkoff
8. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease
HaiFeng Yang and Raouf A. Khalil
9. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology
Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Roberto Levi